Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)

At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenqi, Fan, Yanfeng, Li, Meng, Yang, Linqi, Zhang, Zhenya, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463246/
https://www.ncbi.nlm.nih.gov/pubmed/34567285
http://dx.doi.org/10.1155/2021/4894022
Descripción
Sumario:At present, the use of the common chemotherapy regimen CHOP/R-CHOP for diffuse large B-cell lymphoma (DLBCL) has some shortcomings, especially for relapsed and refractory DLBCL. CD47 is now considered as a prominent target in cancer therapies, and CD47 blockade mainly inhibits the CD47-SIRPα axis to prevent tumor immune escape. Here, we evaluated the effects of the latest CD47 antibodies reported and the correlations of closely related genes with CD47 in this disease. In the future, therapeutic strategies for DLBCL will focus on multitarget antibody combined treatment and multigene joint attacks.

Ejemplares similares